Home

United States Chinese Anti-Cancer Association, is organized under the "general Not for Profit Corporation
Act" of the State of California, United States, exclusively for educational, scientific and charitable purposes.

The mission of the association is:

1、Facilitates collaborations among Chinese American professionals in the field of cancer research, treatment and prevention;

2、Promotes knowledge and information exchange between the professionals in the United States and China;

3、Provides educational information to serve cancer patients, their families, and the community.

The Latest News

USCACA Welcomes Its New President – Shi-Yong Sun, Ph.D.

On August 25th, USCACA Executive Office held a meeting to initiate the election process following the bylaws. The meeting was hosted by USCACA Managing Director, Dr. Li Yan,and General Secretary, Dr. YunGuang Tong. At the meeting, Shiyong Sun, nominated by USCACA Board, was elected as the new President of USCACA unanimously by the Executive Officers. After being elected, Shi-Yong shared his passion and vision for the organization.

蓄势待发丨2021 ADC药物360°高峰论坛

“2021 ADC药物360°高峰论坛(暨Pre-ASCO China Summit #3)”由美中抗癌协会(USCACA)和世易医健(eChinaHealth)共同主办,主题聚焦时下热度正高的ADC药物领域。

目前国外已有10余款ADC药物获批上市,市场规模预计在百亿美元。市场上虽然尚无获批的中国产品上市,但众多国内药企争相进入ADC药物研发赛道,加码布局这一领域,商业化元年正在到来。

本次论坛将从“产+学+研+资+临”方面,全方位360维度分析当前ADC药物的临床突破和下一代研究方向。

精 彩 日 程

5月29日 上海虹桥锦江大酒店

08:50 会议主席致辞
陈小祥 博士
和铂医药
USCACA执委
CSCO临床研究专家委员会副主委

09:00 Pre-ASCO China Summit #3:
ADC药物国际临床研究进展
中外主席

李进 教授
同济大学东方医院
中国临床肿瘤学会前任理事长

Yung-Jue Bang 教授
韩国首尔大学
韩国临床肿瘤学会前任主席

世易医学汇丨协议商谈,共同开发,商业双赢

5月22日北京时间上午9点,由美中抗癌协会(USCACA)和世易医健(eChinaHealth)共同主办的“2021 Pre-ASCO China Summit #2: 中国创新药海外授权和国际化”顺利举行。

本次论坛荣幸的邀请到百济-诺华合作项目负责人:百济神州首席商务执行官Angus Grant博士和诺华制药肿瘤研发部负责人 Jeff Legos博士。他们将在“协议商谈,共同开发,商业双赢”等方面分享合作双方的战略思考和未来发展方向。

接下来让我们回顾一下本次会议的精彩亮点!

会议亮点
原力生命科学首席研发官/USCACA 美中抗癌协会执行委员 Roger Luo博士代表会议主办方美中抗癌协会和世易医健欢迎大家参加会议。

Sponsor and Partner